Cover Image
市場調查報告書

蛋白質表現系統市場:現狀及未來的機會

Protein Expression Systems Market: Current Landscape and Future Opportunities

出版商 ROOTS ANALYSIS 商品編碼 339742
出版日期 內容資訊 英文 249 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
蛋白質表現系統市場:現狀及未來的機會 Protein Expression Systems Market: Current Landscape and Future Opportunities
出版日期: 2015年09月02日 內容資訊: 英文 249 Pages
簡介

由於遺傳因子工程學和基因複製技術的進步,在研究、治療、產業用可隔離和表現異種組調換蛋白質。由於酵素、抗體、疫苗生產等大規模應用而需要大量的蛋白質。為了對應這樣的需求,開發細菌、酵母菌、昆蟲、哺乳類細胞等各種表現系統 。

本報告提供蛋白質表現系統市場相關調查、各種表現系統的概要與開發平台趨勢、今後的成長預測,以及參與企業簡介,及今後的機會分析等彙整資料。

第1章 序論

第2章 摘要整理

第3章 簡介

  • 本章概要
  • 蛋白質合成:概要
  • 表現系統的組調換蛋白質產生
  • 蛋白質表現方法
  • 一般表現系統採用物比較

第4章 市場概要

  • 本章概要
  • 哺乳類
  • 細菌
  • 酵母菌
  • 昆蟲
  • 植物
  • 無細胞
  • 其他
  • 表現系統的萬能性

第5章 表現系統:主要的特徵與產品

  • 本章概要
  • 常見哺乳類表現系統
  • 常見細菌表現系統
  • 常見酵母菌表現系統
  • 常見昆蟲表現系統
  • 常見植物表現系統
  • 常見無細胞表現系統

第6章 企業簡介

  • 本章概要
  • Agilent Technologies
  • Clontech
  • Geneva Biotech
  • Life Technologies / Thermo Fisher
  • Life Sensors
  • Lonza
  • Merck Millipore
  • New England Biolabs
  • Oxford Expression Technologies
  • Pfenex
  • Promega Corporation
  • Research Corporation Technology

第7章 CMO服務

  • 本章概要
  • 生物醫藥品CMO:地區分析
  • 生物醫藥品CMO:業務規模分析
  • 生物醫藥品CMO:能力分析
  • 生物醫藥品CMO:生物反應器的種類
  • 今後預測

第8章 機會分析

  • 本章概要
  • 已上市生技藥品
  • 開發平台藥物
  • 生技仿製藥

第9章 SWOT分析

第10章 採訪原稿

第11章 結論

第12章 附錄1:資料表

第13章 附錄2:企業、組織清單

圖表

目錄
Product Code: RA10047

Advances in genetic engineering and cloning techniques have allowed isolation and expression of heterologous and recombinant proteins for research, therapeutic and industrial uses. Large scale applications such as enzyme, antibody or vaccine production require high amounts of protein. This demands that the system producing protein must be easy to culture, allow rapid cell growth and provide good yield. Various expression systems based on the machinery of bacteria, yeast, insect or mammalian cells have been developed to cater to these demands.

Protein synthesis occurs differently in prokaryotic and eukaryotic systems; the need for post translational modifications adds a level of complexity in the latter case. Newer expression systems utilising yeast and insect cells as host are gaining momentum due to favourable culture conditions and final end products. Pichia and Sf9/Sf21 host cells have emerged as the most commonly used systems in these categories, respectively. Some plant based technologies express protein rapidly, unlike the traditional methods of production in transgenic plants. Several other expression systems based on protozoa and fungi have also demonstrated effective protein expression. In addition, cell free expression systems have also been developed and are gaining momentum in the market.

The highly lucrative biologics market presents a huge opportunity for such systems. Both large and small companies in this sector have developed proprietary recombinant protein expression techniques to carve out their own share of the multi-billion dollar market. The increasing demand for biologics has led to the involvement of various CMOs providing services in protein expression. However, there are sometechnical shortcomings in current platforms which need to be dealt with to maximize the available opportunity. The opportunity, overall, will continue to increase manifold with the approval of several new biologics and biosimilars in the coming few years.

Synopsis:

The “Protein Expression Systems Market: Current Landscape and Future Opportunities” report provides an extensive study of the various expression systems commercially available for the purpose of expressing the desired proteins. Selecting an effective and reliable expression system is one of the pre-requisites for pharma companies before they start proof of concept studies for biological molecules. It is well known that a particular expression system is not suitable to express every kind of protein. As such, there are several different types of platforms available to meet the growing demand.

With an extensive pipeline of biologic drugs, protein expression systems are likely to continue to garner significant attention from the biopharmaceutical industry. The report covers various aspects such as key features of these systems, associated products, licensing and services portfolio. We have also covered specific details on CMOs manufacturing biopharmaceutical products highlighting their capabilities, geographical location, scale of operation, type of biologics being manufactured and expression systems being used.

In addition, the report highlights the future growth prospects with respect to manufacturing biological molecules. We have analyzed the overall biologics pipeline and provided specific details on some important classes such as antibody drug conjugates (ADCs) and bispecific antibodies. Further, we have highlighted the emerging opportunity presented by the ongoing development of biosimilars. For the purposes of the study, we interviewed important stakeholders to solicit their opinions around the upcoming opportunities and challenges which must be considered for a more inclusive growth. Examples of companies we interviewed include Research Corporation Technologies, iBio and Jena Bioscience.

Example Highlights:

  • 1. Presently bacterial and mammalian cell based systems are the preferred choice for therapeutic protein expression. Bacterial systems are preferred for their low cost, high productivity and rapid results. Mammalian cells, on the other hand, have the ability to generate proteins with folding and post-translational modification identical to native endogenous protein.
  • 2. A number of new host systems have come into the market offering advantages such as higher protein yield, diminishing susceptibility to viral contamination and easy scale up. Among these are yeast, insect, and also certain plant based protein expression systems. Cell free systems have also gained momentum and allow direct manipulation of the chemical environment that rapidly generates significant amounts of the required protein.
  • 3. In addition to the well-established firms such as Agilent Technologies, Clontech, Life Technologies, Lonza, Merck Millipore, Promega Corporation and Research Corporation Technologies, several smaller companies too have developed robust proprietary expression systems. Examples (in alphabetic order) include Dyadic International, Geneva Biotech, Greenovation, iBio, Jena Bioscience, New England Biolabs, Oxford Expression Technologies, Pfenex and Scarab Genomics.
  • 4. The highly lucrative biologics market presents a huge opportunity for protein expression systems. The biologics market is considered to be worth over USD 200 billion and has an increasing number of therapeutically relevant protein based molecules in the pipeline.
  • 5. The outlook for CMOs is highly promising. In our study, we identified over 160 biopharmaceutical CMOs (accounting for over 250 production facilities worldwide), which provide protein expression services. With around 900 biologics in the pipeline and 150 marketed products, CMOs stand to benefit tremendously from this growing trend.
  • 6. Technological improvements including the use of highly evolved expression elements such as designer promoters for obtaining higher translational efficiency, genome engineering to facilitate better homologous recombination and computer-controlled feeding algorithms are likely to further maximize output and yield.

Research Methodology:

Most of the data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines:

Chapter 2 provides an executive summary of the insights captured during our research. The summary offers a high level view on the present scenario of protein expression systems market and the likely growth opportunities in the future.

Chapter 3 provides a general introduction to protein expression systems. We have briefly discussedthe basic concepts related to protein synthesis and recombinant protein expression in such systems. The chapter also covers an overview on different types of expression systems that are used for expressing protein along with their advantages and disadvantages.

Chapter 4 presents a comprehensive list of expressions systems, categorized based on the host cell in which the protein is expressed. In addition, we have also listed the expression systems being developed by various academic institutes.

Chapter 5 provides additional details on some expression systems which are relatively more popular within each specific category. Each profile highlights the key attributes such as yield, time to express protein, quality of product, associated cost, scale-up and culture requirements.

Chapter 6 presents profiles of 12 leading companies in this domain. Each company profile includes information such as company overview, financial performance, expression systems, product portfolio and licensing and partnership agreements made with other companies.

Chapter 7 elaborates on the participation of contract manufacturers in biopharmaceuticals manufacturing. This chapter includes an extensive analysis of CMOs and highlights their geographical location, manufacturing capabilities in terms of type of biologics manufactured and scale of operation, expression systems used and fermentation capacity.

Chapter 8 focuses on highlighting the opportunity areas for companies with proprietary expression systems. It provides a detailed overview on biologics currently being developed and specifically covers the pipeline of some of the important drug classes such as antibody drug conjugates and bispecific antibodies. We have also highlighted the opportunity presented by biosimilars, a key growth prospect for developers of expression systems.

Chapter 9 provides our analysis of the strengths, weaknesses, opportunities and threats in the protein expression systems market. This section captures key elements likely to influence future growth in the industry.

Chapter 10 summarizes the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

Chapter 11 provides three interview transcripts based on our discussion with senior stakeholders in the industry. The companies interviewed included Research Corporation Technologies, iBio and Jena Bioscience.

Chapters 12 and 13 are appendices and provide the list of companies and tabulated data for all the figures presented in the report.

Table of Contents

1. Preface

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. Executive Summary

3. Introduction

  • 3.1. Chapter Overview
  • 3.2. Protein Synthesis: An Overview
  • 3.3. Recombinant Protein Production in Expression Systems
  • 3.4. Protein Expression Methods
    • 3.4.1. In Vivo Protein Expression
      • 3.4.1.1. Mammalian Protein Expression System
      • 3.4.1.2. Bacterial Protein Expression System
      • 3.4.1.3. Yeast Protein Expression System
      • 3.4.1.4. Insect Protein Expression System
      • 3.4.1.5. Plant Protein Expression System
      • 3.4.1.6. Protozoan Protein Expression System
      • 3.4.1.7. Algae Protein Expression System
    • 3.4.2. In Vitro (Cell Free) Protein Expression
    • 3.4.3. Chemical Protein Synthesis
  • 3.5. Comparison of Commonly Used Expression Systems

4. Market Overview

  • 4.1. Chapter Overview
  • 4.2. Mammalian Expression Systems
  • 4.3. Bacterial Expression Systems
  • 4.4. Yeast Expression Systems
  • 4.5. Insect Expression Systems
  • 4.6. Plant Expression Systems
  • 4.7. Cell-Free Expression Systems
  • 4.8. Other Expression Systems
  • 4.9. Universities with Proprietary Expression Systems

5. Expression Systems: Key Features and Products

  • 5.1. Chapter Overview
  • 5.2. Well-Known Mammalian Expression Systems
    • 5.2.1. PER.C6 Technology (Crucell / Janssen)
      • 5.2.1.1. Granted Patents
      • 5.2.1.2. Key Features
      • 5.2.1.3. Products
      • 5.2.1.4. Licensing and Services
    • 5.2.2. GS Gene Expression System (Lonza)
      • 5.2.2.1. Key Features
      • 5.2.2.2. Products
      • 5.2.2.3. Licensing and Services
  • 5.3. Well-Known Bacterial Expression Systems
    • 5.3.1. Pfenex Technology (Pfenex)
      • 5.3.1.1. Granted Patents
      • 5.3.1.2. Key Features
      • 5.3.1.3. Products
      • 5.3.1.4. Licensing and Services
    • 5.3.2. XS Bacillus Expression System (Lonza)
      • 5.3.2.1. Key Features
      • 5.3.2.2. Comparison of XS Expression Systems
      • 5.3.2.3. Products
      • 5.3.2.4. Licensing and Services
  • 5.4. Well-Known Yeast Expression Systems
    • 5.4.1. Pichia Secretory SUMOstar Expression System (LifeSensors)
      • 5.4.1.1. Granted Patents
      • 5.4.1.2. Key Features
      • 5.4.1.3. Products
      • 5.4.1.4. Licensing and Services
    • 5.4.2. Pichia Glycoswitch Protein Expression System (Research Corporation Technologies)
      • 5.4.2.1. Key Features
      • 5.4.2.2. Products
      • 5.4.2.3. Licensing and Services
  • 5.5. Well-Known Insect Expression Systems
    • 5.5.1. Bac-To-Bac Baculovirus Expression System (Invitrogen / Life Technologies)
      • 5.5.1.1. Key Features
      • 5.5.1.2. Products
      • 5.5.1.3. Licensing and Services
    • 5.5.2. Drosophila Expression System (Invitrogen / Life Technologies)
      • 5.5.2.1. Key Features
      • 5.5.2.2. Products
      • 5.5.2.3. Licensing and Services
    • 5.5.3. BacPAK Protein Expression Systems (Clontech)
      • 5.5.3.1. Key Features
      • 5.5.3.2. Products
      • 5.5.3.3. Licensing and Services
    • 5.5.4. flashBAC Expression System (Oxford Expression Technologies)
      • 5.5.4.1. Granted Patents
      • 5.5.4.2. Key Features
      • 5.5.4.3. Products
      • 5.5.4.4. Licensing and Services
  • 5.6. Well-Known Plant Expression Systems
    • 5.6.1. BryoTechnology (Greenovation Biotech)
      • 5.6.1.1. Key Features
      • 5.6.1.2. Products
      • 5.6.1.3. Licensing and Services
    • 5.6.2. iBioLaunch Technology (iBio)
      • 5.6.2.1. Granted Patents
      • 5.6.2.2. Key Features
      • 5.6.2.3. Products
      • 5.6.2.4. Licensing and Services
  • 5.7. Well-Known Cell-Free Expression Systems
    • 5.7.1. Xpress CF Protein Synthesis Platform (Sutro Biopharma)
    • 5.7.1.1. Key Features
    • 5.7.1.2. Products
    • 5.7.1.3. Licensing and Services
    • 5.7.2. TnT SP6 High-Yield Wheat Germ Protein Expression System (Promega Corporation)
      • 5.7.2.1. Key Features
      • 5.7.2.2. Products and Licensing
  • 5.8. Other Expression Systems
    • 5.8.1. LEXSY Protein Expression System (Jena Bioscience)
      • 5.8.1.1. Key Features
      • 5.8.1.2. Products
      • 5.8.1.3. Licensing and Services
    • 5.8.2. C1 Expression System (Dyadic International)
      • 5.8.2.1. Granted Patents
      • 5.8.2.2. Key Features
      • 5.8.2.3. Products
      • 5.8.2.4. Licensing and Services
    • 5.8.3. Cipex System (Cilian)
      • 5.8.3.1. Granted Patents
      • 5.8.3.2. Key Features
      • 5.8.3.3. Products
      • 5.8.3.4. Licensing and Services

6. Company Profiles

  • 6.1. Chapter Overview
  • 6.2. Agilent Technologies
    • 6.2.1. Overview
    • 6.2.2. Financial Performance
    • 6.2.3. Technology Platforms
      • 6.2.3.1. PathDetect Trans Reporting Systems
      • 6.2.3.2. PathDetect Cis-Reporting Systems
      • 6.2.3.3. LacSwitch II Inducible Mammalian Expression System
    • 6.2.4. Product Portfolio
  • 6.3. Clontech
    • 6.3.1. Overview
    • 6.3.2. Financial Performance
    • 6.3.3. Technical Platforms
      • 6.3.3.1. HAT Protein Expression and Purification System
      • 6.3.3.2. pET Expression System
      • 6.3.3.3. Baculovirus Expression Systems (BacPAK Method)
    • 6.3.4. Product Portfolio
  • 6.4. Geneva Biotech
    • 6.4.1. Technology Platforms
      • 6.4.1.1. MultiBac™ Expression System
      • 6.4.1.2. SweetBac™ Expression System
      • 6.4.1.3. VLP Factory™
      • 6.4.1.4. iBac™
      • 6.4.1.5. ManuBac™
      • 6.4.1.6. MultiBacMam™
      • 6.4.1.7. MultiMam™ Transient
      • 6.4.1.8. MultiMam™ Stable
      • 6.4.1.9. Multicoli™
    • 6.4.2. Product Portfolio
    • 6.4.3. Licensing and Partnerships
  • 6.5. Life Technologies / Thermo Fisher
    • 6.5.1. Overview
    • 6.5.2. Financial Performance
    • 6.5.3. Technology Platforms
      • 6.5.3.1. Geneart® Algae Expression and Engineering Kits
      • 6.5.3.2. Scalable Transient Protein Expression Systems
      • 6.5.3.3. Viral Gene Delivery for Protein Expression (Viral Power™)
      • 6.5.3.4. Membrane Pro Expression Systems
      • 6.5.3.5. T-REx Systems
      • 6.5.3.6. Champion™ Pet Expression Systems
      • 6.5.3.7. Bac-To-Bac® Baculovirus Expression System
      • 6.5.3.8. Bac-To-Bac® HBM TOPO® Secreted Expression System
      • 6.5.3.9. BaculoDirect™ Baculovirus Expression System
      • 6.5.3.10. PichiaPinkTM Yeast Expression Systems
      • 6.5.3.11. Pichia Expression Systems
      • 6.5.3.12. MembraneMaxTM Protein Expression Kits
      • 6.5.3.13. Meddes Drosophila Expression Systems
    • 6.5.4. Product Portfolio
    • 6.5.5. Licensing and Partnerships
  • 6.6. Life Sensors
    • 6.6.1. Overview
    • 6.6.2. Technology Platforms
      • 6.6.2.1. SUMO E.coli Expression Systems
      • 6.6.2.2. SUMO Mammalian Expression Systems
      • 6.6.2.3. SUMO Insect Expression Systems
      • 6.6.2.4. SUMO Yeast Expression Systems
    • 6.6.3. Product Portfolio
    • 6.6.4. Licensing and Partnerships
  • 6.7. Lonza
    • 6.7.1. Overview
    • 6.7.2. Financial Performance
    • 6.7.3. Technology Platforms
      • 6.7.3.1. GS Gene Expression System
      • 6.7.3.2. GS Xceed Gene Expression System
      • 6.7.3.3. XS E.coli Expression Systems
      • 6.7.3.4. XS Pichia Expression Systems
      • 6.7.3.5. XS Bacillus Expression Systems
    • 6.7.4. Product Portfolio
    • 6.7.5. Licensing and Partnerships
  • 6.8. Merck Millipore
    • 6.8.1. Overview
    • 6.8.2. Financial Performance
    • 6.8.3. Technology Platforms
      • 6.8.3.1. Insect direct® System
      • 6.8.3.2. UCOE Expression Technology
      • 6.8.3.3. pET Expression System
    • 6.8.4. Product Portfolio
    • 6.8.5. Licensing and Partnerships
  • 6.9. New England Biolabs
    • 6.9.1. Overview
    • 6.9.2. Technology Platforms
      • 6.9.2.1. Gene Expression System
      • 6.9.2.2. Yeast Protein Expression Kit
      • 6.9.2.3. Cell-Free Expression Systems
    • 6.9.3. Product Portfolio
    • 6.9.4. Licensing and Partnerships
  • 6.10. Oxford Expression Technologies
    • 6.10.1. Overview
    • 6.10.2. Technology Platforms
      • 6.10.2.1. flashBAC Expression Systems
      • 6.10.2.2. flashBAC Ultra Baculovirus Expression System
      • 6.10.2.3. BacMam Expression Systems
    • 6.10.3. Product Portfolio
    • 6.10.4. Licensing and Partnerships
  • 6.11. Pfenex (Dow Pharma)
    • 6.11.1. Overview
    • 6.11.2. Financial Performance
    • 6.11.3. Technology Platforms
    • 6.11.4. Product Portfolio
    • 6.11.5. Licensing and Partnerships
  • 6.12. Promega Corporation
    • 6.12.1. Overview
    • 6.12.2. Financial Performance
    • 6.12.3. Technology Platforms
      • 6.12.3.1. TNT® Quick Systems
      • 6.12.3.2. TNT® T7 Insect Cell Extract Protein Expression System
      • 6.12.3.3. TNT® SP6 High-Yield Protein Expression System
      • 6.12.3.4. Regulated Mammalian Expression System
      • 6.12.3.5. S30 T7 High-Yield Protein Expression System
    • 6.12.4. Product Portfolio
  • 6.13. Research Corporation Technology
    • 6.13.1. Overview
    • 6.13.2. Technology Platforms
      • 6.13.2.1. Pichia Classic Protein Expression System
      • 6.13.2.2. Pichia Glycoswitch Protein Expression System
      • 6.13.2.3. Endotoxin-Free Clearcoli Expression System
    • 6.13.3. Product Portfolio
    • 6.13.4. Licensing and Partnerships

7. CMO Services

  • 7.1. Chapter Overview
  • 7.2. Biopharmaceutical CMOs: Regional Analysis
  • 7.3. Biopharmaceutical CMOs: Analysis by Scale of Operation
  • 7.4. Biopharmaceutical CMOs: Capability Analysis
    • 7.4.1. Distribution by Type of Biologic Molecule
    • 7.4.2. Distribution by Expression Systems
  • 7.5. Biopharmaceutical CMOs: Type of Bioreactors
  • 7.6. Roots Analysis Perspective

8. Opportunity Analysis

  • 8.1. Chapter Overview
  • 8.2. Marketed Biologics
  • 8.3. Pipeline Biologics
    • 8.3.1. Case-In-Point: Antibody Drug Conjugates
      • 8.3.1.1. Development Pipeline
      • 8.3.1.2. Pipeline Analysis
    • 8.3.2. Case-In-Point: Bispecific Antibodies
      • 8.3.2.1. Drugs Indicated for Oncological Diseases
      • 8.3.2.2. Drugs Indicated for Non-Oncological Diseases
      • 8.3.2.3. Drugs in Preclinical Trials
      • 8.3.2.4. Pipeline Analysis
    • 8.3.3. Case-In-Point: Subcutaneous Biologics
      • 8.3.3.1. Pipeline Analysis
      • 8.3.3.1.1. Distribution by Type of Molecule
      • 8.3.3.1.2. Distribution by Phase of Development
      • 8.3.3.1.3. Distribution by Indication
  • 8.4. Biosimilars
    • 8.4.1. Biosimilars: Distribution by Geography
    • 8.4.2. Biosimilars: Distribution by Phase of Development
    • 8.4.3. Biosimilars: Distribution by Product Category
  • 8.5. Roots Analysis Perspective

9. SWOT Analysis

  • 9.1. Overview
  • 9.2. Strengths
  • 9.3. Weaknesses
  • 9.4. Opportunities
  • 9.5. Threats

10. Interview Transcripts

  • 10.1. Chapter Overview
  • 10.2. Interview 1: Dr. Reinhard Breitling, Head of LEXSY Division, Jena Bioscience
  • 10.3. Interview 2: Dr. Terence E Ryan, Senior Vice President and Chief Scientific Officer, iBio
  • 10.4. Interview 3: Dr. Kurt R. Gehlsen, Vice President and Chief Scientific Officer, Research Corporation Technologies

11. Conclusion

  • 11.1. Protein Expression: A Well Established Process for Producing Recombinant Proteins
  • 11.2. Mammalian and Bacterial Systems are Widely Popular; New Systems are Gaining Attention
  • 11.3. Biologics: A High Opportunity Market
  • 11.4. Highly Promising Outlook for CMOs
  • 11.5. Concluding Remarks

12. Appendix 1: Tabulated Data

13. Appendix 2: List of Companies and Organizations

List of Figures:

  • Figure 3.1: Protein Synthesis: An Overview
  • Figure 3.2: Recombinant Protein Expression Process
  • Figure 3.3: Types of Expression Systems
  • Figure 4.1: Expression Systems: Distribution by Type of Host
  • Figure 6.1: Agilent Technologies: Historical Sales (USD Billion), 2010-2014
  • Figure 6.2: Agilent Technologies: Sales by Business Segments (USD Billion), 2014
  • Figure 6.3: Takara Bio: Historical Sales (JPY Billion), 2010-2014
  • Figure 6.4: Takara Bio: Sales by Business Segments (JPY Billion), 2014
  • Figure 6.5: Thermo Fisher: Historical Sales (USD Billion), 2010-2014
  • Figure 6.6: Lonza: Historical Sales (CHF Billion), 2011- 2014
  • Figure 6.7: Merck Millipore: Historical Sales (EUR Billion), 2010-2014
  • Figure 6.8: Pfenex: Historical Sales (USD Million), 2012-2014
  • Figure 6.9: Promega: Historical Sales (USD Million), 2008 - 2012
  • Figure 7.1: Biopharmaceutical CMOs: Geographical Locations
  • Figure 7.2: Biopharmaceutical CMOs: Distribution by Regions
  • Figure 7.3: Biopharmaceutical CMOs: Distribution by Scale of Operation
  • Figure 7.4: Biopharmaceutical CMOs: Distribution by Type of Biologic Molecule
  • Figure 7.5: Biopharmaceutical CMOs: Distribution by Expression Systems
  • Figure 7.6: Single Use Bioreactors: Advantages and Disadvantages
  • Figure 8.1: Approved Biologics: Distribution by Type of Host Cell
  • Figure 8.2: Pipeline Biologics: Distribution by Type of Molecule
  • Figure 8.3: Antibody Drug Conjugates Pipeline: Distribution by Phase of Development
  • Figure 8.4: Bispecific Antibodies Pipeline: Distribution by Phase of Development
  • Figure 8.5: Subcutaneous Biologics Pipeline: Distribution by Type of Molecule
  • Figure 8.6: Subcutaneous Biologics Pipeline: Distribution by Phase of Development
  • Figure 8.7: Subcutaneous Biologics Pipeline: Leading Indications / Therapeutic Areas
  • Figure 8.8: Biosimilars: Distribution by Geography
  • Figure 8.9: Biosimilars: Distribution by Phase of Development
  • Figure 8.10: Biosimilars: Distribution by Product Category
  • Figure 11.1: Pipeline Biologics: Distribution by Type of Molecule
  • Figure 11.2: Biopharmaceutical CMOs: Distribution by Expression Systems

List of Tables:

  • Table 3.1: Comparison of Expression Systems
  • Table 4.1: List of Mammalian Expression Systems
  • Table 4.2: List of Bacterial Expression Systems
  • Table 4.3: List of Yeast Expression Systems
  • Table 4.4: List of Insect Expression Systems
  • Table 4.5: List of Plant Expression Systems
  • Table 4.6: List of Cell-Free Expression Systems
  • Table 4.7: List of Other Expression Systems
  • Table 4.8: List of Universities / Academia with Expression Systems
  • Table 5.1: PER.C6 Cell Line Technology: Product Portfolio
  • Table 5.2: Pfenex Technology: Product Portfolio
  • Table 5.3: Pfenex Technology: Partnerships/Deals (2012-2015)
  • Table 5.4: XS Expression Systems: Comparison
  • Table 5.5: Bac-to-Bac Baculovirus Expression System: Product Portfolio
  • Table 5.6: Drosophila Expression System: Product Portfolio
  • Table 5.7: Drosophila Expression System: Expressed Products
  • Table 5.8: BacPAK Protein Expression Kits
  • Table 5.9: flashBAC Expression Vector System: Expression Kits
  • Table 5.10: flashBAC Expression System: Licensing Deals (2012-2015)
  • Table 5.11: BryoTechnology: Product Portfolio
  • Table 5.12: iBioLaunch Technology: Product Portfolio
  • Table 5.13: iBioLaunch Technology: Partnerships/Deals (2012-2015)
  • Table 5.14: Xpress CF Protein Synthesis Platform: Product Portfolio
  • Table 5.15: Xpress CF Technology: Licensing Deals (2012-2015)
  • Table 5.16: LEXSY Expression Kits
  • Table 6.1: Agilent Technologies: Product Portfolio
  • Table 6.2: Clontech Laboratories: Products of Expression Systems
  • Table 6.3: Geneva Biotech: Product Portfolio
  • Table 6.4: Life Technologies: Product Portfolio
  • Table 6.5: Lifesensors: Product Portfolio
  • Table 6.6: Lonza: Product Portfolio
  • Table 6.8: Merck Millipore: Product Portfolio
  • Table 6.9: New England Biolabs: Product Portfolio
  • Table 6.10: Oxford Expression Technologies: Product Portfolio
  • Table 6.11: Oxford Expression Technologies: Partnerships
  • Table 6.12: Pfenex Technology: Product Portfolio
  • Table 6.13: Pfenex Technology: Partnerships (2012-2015)
  • Table 6.14: Promega Corporation: Product Portfolio
  • Table 6.15: Research Corporation Technology: Product Portfolio
  • Table 7.1: Biopharmaceutical CMOs: Scale of Operation
  • Table 7.2: Biopharmaceutical CMOs: Type of Biologics
  • Table 7.3: Biopharmaceutical CMOs: Type of Expression Systems
  • Table 7.4: Biopharmaceutical CMOs: Type of Bioreactor
  • Table 8.1: Marketed Biologics
  • Table 8.2: Antibody Drug Conjugates: Clinical Development Pipeline
  • Table 8.3: Antibody Drug Conjugates: Preclinical / Discovery Development Pipeline
  • Table 8.4: Bispecific Antibodies: Clinical Development Pipeline (Oncology)
  • Table 8.5: Bispecific Antibodies: Clinical Development Pipeline (Non-Oncology)
  • Table 8.6: Bispecific Antibodies: Preclinical / Discovery Development Pipeline
  • Table 8.6: Subcutaneous Biologics: Development Pipeline
  • Table 8.7: Biosimilars: Development Pipeline
  • Table 9.1: SWOT Analysis
  • Table 9.2: Protein Expression Systems for Co-Expression
  • Table 12.1: Expression Systems: Distribution by Type of Host
  • Table 12.2: Agilent Technologies: Historical Sales (USD Billion), 2010-2014
  • Table 12.3: Agilent Technologies: Sales of Business Segments (USD Billion), 2014
  • Table 12.4: Takara Bio: Historical Sales (JPY Billion), 2010-2014
  • Table 12.5: Takara Bio: Sales of Business Segments (JPY Billion), 2014
  • Table 12.6: Thermo Fisher: Historical Sales (USD Billion), 2010-2014
  • Table 12.7: Lonza: Historical Sales (CHF Billion), 2011- 2014
  • Table 12.8: Merck Millipore: Historical Sales (EUR Billion), 2010-2014
  • Table 12.9: Pfenex: Historical Sales (USD Million), 2012- 2014
  • Table 12.10: Promega: Historical Sales (USD Million), 2008-2012
  • Table 12.11: Approved Biologics: Distribution by Type of Host Cell
  • Table 12.12: Pipeline Biologics: Distribution by Type of Molecule
  • Table 12.13: ADCs Pipeline: Distribution by Phase of Development
  • Table 12.14: Bispecific Antibodies Pipeline: Distribution by Phase of Development
  • Table 12.15: Subcutaneous Biologics Pipeline: Distribution by Type of Molecule
  • Table 12.16: Subcutaneous Biologics Pipeline: Distribution by Phase of Development
  • Table 12.17: Subcutaneous Biologics Pipeline: Leading Indications / Therapeutic Areas
  • Table 12.18: Biosimilars: Distribution by Phase of Development

Listed Companies:

The following companies and organizations have been mentioned in the report:

  • 1. 3P Biopharmaceuticals
  • 2. 5 PRIME
  • 3. AAIPharma Services
  • 4. AbbVie
  • 5. AbGenomics
  • 6. Abnova
  • 7. AdAlta
  • 8. ADC Therapeutics
  • 9. Aeras
  • 10. Affinicon
  • 11. Affinity Life Sciences
  • 12. Agilent Technologies
  • 13. Ajinomoto Althea
  • 14. Aldevron
  • 15. Allele Biotechnology
  • 16. Alliance Medical Products (Siegfried)
  • 17. Alpax Pharmaceuticals
  • 18. Ambrx
  • 19. AMEGA Biotech
  • 20. AMYRA Biotech
  • 21. Apotex Fermentation
  • 22. Aragen Bioscience
  • 23. Artes Biotechnology
  • 24. Asahi Glass Co.
  • 25. Astellas
  • 26. AthenaES
  • 27. AutekBio
  • 28. Avecia
  • 29. Avesta Biotherapeutics and Research
  • 30. Avid Bioservices
  • 31. Batavia Bioservices
  • 32. Bavarian Nordic
  • 33. Baxter BioPharma Solutions
  • 34. Bayer Healthcare
  • 35. BD Biosciences
  • 36. Bharat Biotech
  • 37. BIBITEC
  • 38. Binex Co.
  • 39. Bio Elpida
  • 40. BioCision
  • 41. Bio-Concept
  • 42. BioConnection
  • 43. BioConvergence
  • 44. BioGenomics
  • 45. BioGrammatics
  • 46. Bioinformatics
  • 47. BioIngenium
  • 48. BioMARC
  • 49. Biomay
  • 50. BIOMEVA
  • 51. Bioneer
  • 52. Frederick National Laboratory for Cancer Research (FNLCR)
  • 53. BioPharmaceuticals Australia
  • 54. Bio-Rad Laboratories
  • 55. BioReliance
  • 56. BioSavita
  • 57. BioSynergy
  • 58. Biotechnique
  • 59. Biotechpharma
  • 60. Biotest
  • 61. BioVectra
  • 62. Biovest International
  • 63. Biovian
  • 64. Biovolutions
  • 65. BioXcellence (Boehringer Ingelheim)
  • 66. Bristol Myers Squibb
  • 67. BroadOak Capital Partners
  • 68. Cantab Biopharmaceuticals
  • 69. Catalent
  • 70. Catalyst biosciences
  • 71. Cellca
  • 72. Celldex Therapeutics
  • 73. CellFree Sciences
  • 74. Celgene
  • 75. Celonic
  • 76. Center for Biocatalysis and Bioprocessing, The University of Iowa
  • 77. Cerbios-Pharma
  • 78. CEVEC Pharmaceuticals
  • 79. ChemPartner
  • 80. Cilian
  • 81. Clontech (a Takara Bio Company)
  • 82. CMC Biologics
  • 83. Cobra Biologics
  • 84. Cognate BioServices
  • 85. Concord Biotech
  • 86. Cook Pharmica
  • 87. Creative Biolabs
  • 88. Crucell
  • 89. Cytovance Biologics
  • 90. Dalton Pharma Services
  • 91. Development Center for Biotechnology, Taiwan
  • 92. DisperSol technologies
  • 93. DM BIO DONG-A meiji
  • 94. Dow Pharma
  • 95. Dyadic International
  • 96. Emergent BioSolutions
  • 97. Enteris BioPharma
  • 98. Esperance Pharmaceuticals
  • 99. EUCODIS Bioscience
  • 100. Eurogentec
  • 101. Florida Biologix
  • 102. FormATECH
  • 103. Formation Biologics
  • 104. FUJIFILM Diosynth Biotechnologies
  • 105. Fujirebio Europe
  • 106. Gala Biotech (Catalent subsidiary)
  • 107. GeneCopoeia
  • 108. Geneva Biotech
  • 109. Genhelix (mAbxience group)
  • 110. Genmab
  • 111. GlaxoSmithKline Biopharmaceuticals
  • 112. Glide Pharma
  • 113. Glycotope Group
  • 114. Gold Standard Diagnostics
  • 115. Goodwin Biotechnology
  • 116. Grand River Aseptic Manufacturing
  • 117. GREENOVATION
  • 118. GTP Technology
  • 119. HALIX
  • 120. Hisun Pharmaceuticals USA
  • 121. Hong Kong Institute of Biotechnology
  • 122. Hospira One 2 One
  • 123. iBIO
  • 124. IDT Biologika
  • 125. Inno Biologics
  • 126. Innovent Biologics
  • 127. Intas Pharmaceuticals
  • 128. Integrity Bio
  • 129. Intrexon
  • 130. Irvine Pharmaceutical Services
  • 131. Jena Bioscience
  • 132. Jenrin Discovery
  • 133. KABS Pharmaceutic Services
  • 134. Kairos Therapeutics
  • 135. KBI BioPharma
  • 136. Kemwell Biopharma
  • 137. Kentucky BioProcessing
  • 138. Lampire Biological Laboratories
  • 139. Leinco Technologies
  • 140. LFB Biomanufacturing
  • 141. Life Technologies
  • 142. LifeSensors
  • 143. Lonza
  • 144. Lucigen
  • 145. Lyophilization Services of New England.
  • 146. Mabion
  • 147. Maine Biotechnology Services
  • 148. MassBiologics
  • 149. MBI International
  • 150. Medicago
  • 151. Memorial Sloan-Kettering Cancer centre
  • 152. Menarini Biotech
  • 153. Merck KGaA
  • 154. Merck Millipore
  • 155. Merck Serono
  • 156. Meridian Life Science
  • 157. Miltenyi Biotec
  • 158. MoBiTec
  • 159. Mycenax Biotech
  • 160. Neuland Laboratories
  • 161. New England Biolabs
  • 162. Nextar Chempharma Solutions
  • 163. Norwegian Institute of Public Health
  • 164. Nova Laboratories
  • 165. Novasep
  • 166. Novozymes
  • 167. OctoPlus
  • 168. Omnia Biologics
  • 169. Orflo Technologies
  • 170. OsoBio (AMRI)
  • 171. Oxford Expression Technologies
  • 172. PacificGMP
  • 173. PATH
  • 174. Paragon Bioservices
  • 175. Patheon (unit of DPx Holdings)
  • 176. Pfizer CentreSource
  • 177. PharmaSynth
  • 178. Pharmedartis
  • 179. Phyton Biotech
  • 180. Piramal Pharma Solutions
  • 181. Plant BioScience
  • 182. Plasmid Factory
  • 183. Polymun Scientific
  • 184. Premas Biotech
  • 185. ProBioGen
  • 186. ProteoNic
  • 187. Progenitor Cell Therapy
  • 188. ProMab Biotechnologies
  • 189. Promega Corporation
  • 190. Protalix Biotherapeutics
  • 191. Provantage Biodevelopment Center
  • 192. PX'Therapeutics
  • 193. PYRAMID Laboratories
  • 194. QuaDPharma
  • 195. Reliance Life Sciences
  • 196. Rentschler Biotechnologie
  • 197. Research Corporation Technologies
  • 198. Rhein Biotech
  • 199. Richter-Helm BioTec
  • 200. RiNA
  • 201. SAFC
  • 202. Samsung BioLogics
  • 203. Sandoz
  • 204. Sanofi Pasteur
  • 205. Sanofi CEPiA
  • 206. Sanquin Pharmaceutical Services
  • 207. Scarab Genomics
  • 208. Scil Proteins
  • 209. Shasun
  • 210. SICOR Biotech (Teva)
  • 211. Sigma-Aldrich Corporation
  • 212. Sinocelltech
  • 213. Statens Serum Institut
  • 214. Strides Arcolab
  • 215. Sutro Biopharma
  • 216. Symbiosis Pharmaceutical Services
  • 217. SynCo Bio Partners
  • 218. Syngene (Subsidiary of Biocon)
  • 219. Synthon
  • 220. Sypharma
  • 221. Tetragenetics
  • 222. Teva Pharmaceuticals
  • 223. Therapure Biopharma
  • 224. Thermo Fisher Scientific
  • 225. Toyobo Biologics
  • 226. Trenzyme
  • 227. University of California, San Francisco (UCSF)
  • 228. University of Nebraska
  • 229. Valneva
  • 230. Vetter Pharma International
  • 231. VGXI
  • 232. Vibalogics
  • 233. Vista Biologicals Corp.
  • 234. Vivalis SA
  • 235. VTU Technology
  • 236. Wacker Biotech
  • 237. Waisman Biomanufacturing
  • 238. Wockhardt
  • 239. WuXi AppTec
  • 240. Xbrane Bioscience
  • 241. Xcelience
  • 242. Zhejiang Medicine Co.
  • 243. Zymeworks
Back to Top